Inhibitors of Aurora-A Protein Kinase for the Treatment of Cancer
Nov 7, 2007
Inhibitors of Aurora-A Protein Kinase for the Treatment of Cancer
Aurora-A is an essential enzyme which is required for human cells to multiply. Aurora-A has higher activity than normal in many human cancers and is a target for the development of anti-cancer drugs, some of which are in clinical trials. X-ray crystallography is used to characterise how these small molecules interact with Aurora-A, and these data provide information on how they work and allow the production of a new generation of more potent inhibitors.
Electron density at 2.8 Å resolution around the site where one of the inhibitors binds. Knowledge of the geometry and neighbouring atoms will inform drug development.
Magda Kosmopoulou and Richard Bayliss, Institute of Cancer Research, London
Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.
Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE
Copyright © Diamond Light Source. Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd
Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.